Details for: MYCBP2
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 95.97rCSI 100%PRS 14.07
-
CSI 89.24rCSI 100%PRS 8.21
-
CSI 87.82rCSI 100%PRS 7.81
-
CSI 85.16rCSI 100%PRS 8.81
-
CSI 62.33rCSI 100%PRS 9.19
-
CSI 59.6rCSI 100%PRS 8.34
-
CSI 58.84rCSI 98.77%PRS 8.4
-
CSI 53.93rCSI 97.99%PRS 11.61
-
CSI 53.7rCSI 100%PRS 6.31
-
CSI 46.42rCSI 100%PRS 8.26
-
CSI 42.93rCSI 63.11%PRS 13.07
-
CSI 42.49rCSI 100%PRS 8.1
-
CSI 40.83rCSI 100%PRS 11.33
-
CSI 40.41rCSI 89.28%PRS 10.22
-
CSI 38.91rCSI 100%PRS 13.95
-
CSI 38.74rCSI 89.43%PRS 11.46
-
CSI 36.67rCSI 89.13%PRS 8.17
-
CSI 36.13rCSI 100%PRS 17.18
-
CSI 34.57rCSI 76.08%PRS 8.45
-
CSI 32.49rCSI 100%PRS 9.6
-
CSI 30.48rCSI 95.25%PRS 8.95
-
CSI 30.43rCSI 100%PRS 7.69
-
CSI 30.18rCSI 87.45%PRS 11.04
-
CSI 29.5rCSI 45.06%PRS 14.24
-
CSI 28.23rCSI 56.67%PRS 10.55
-
CSI 27.85rCSI 95.38%PRS 12.46
-
CSI 26.68rCSI 88.42%PRS 13.24
-
CSI 26.37rCSI 94.9%PRS 7.82
-
CSI 25.9rCSI 29.64%PRS 29.11
-
CSI 25.54rCSI 52.48%PRS 14.29
-
CSI 23.91rCSI 90.37%PRS 8.57
-
CSI 21.37rCSI 84.65%PRS 19.82
-
CSI 20.45rCSI 58.51%PRS 25.17
-
CSI 18.93rCSI 94.11%PRS 15.22
-
CSI 17.67rCSI 30.98%PRS 10.51
-
CSI 16.17rCSI 12.46%PRS 12.95
-
CSI 15.9rCSI 43.69%PRS 23.48
-
CSI 15.89rCSI 53.24%PRS 9.78
-
CSI 15.69rCSI 45.41%PRS 16.14
-
CSI 15.64rCSI 92.08%PRS 8.79
-
CSI 15.28rCSI 27.46%PRS 11.89
-
CSI 15.07rCSI 22.74%PRS 14.09
-
CSI 13.69rCSI 93.16%PRS 14.07
-
CSI 13.43rCSI 70.61%PRS 16.16
-
CSI 13.35rCSI 17.85%PRS 18.83
-
CSI 13.32rCSI 20.31%PRS 13.26
-
CSI 13.27rCSI 97.57%PRS 7.54
-
CSI 13.16rCSI 67.39%PRS 12.14
-
CSI 12.9rCSI 18.68%PRS 21.01
-
CSI 12.59rCSI 21.78%PRS 10.83
-
CSI 12.48rCSI 30%PRS 21.32
-
CSI 11.7rCSI 69.1%PRS 14.75
-
CSI 11.55rCSI 74.01%PRS 21.15
-
CSI 11.49rCSI 54.06%PRS 14.07
-
CSI 11.37rCSI 97.95%PRS 5.19
-
CSI 11.3rCSI 9.83%PRS 17.59
-
CSI 11.28rCSI 80.62%PRS 13.72
-
CSI 11.2rCSI 29.22%PRS 22.34
-
CSI 11.16rCSI 30.77%PRS 13.26
-
CSI 11.05rCSI 9.98%PRS 12.63
-
CSI 10.29rCSI 77.32%PRS 12.79
-
CSI 10.1rCSI 47.29%PRS 28.96
-
CSI 9.96rCSI 13.62%PRS 14.31
-
CSI 9.88rCSI 39.75%PRS 33.08
-
CSI 9.5rCSI 45.52%PRS 9.77
-
CSI 9.41rCSI 72.93%PRS 14.19
-
CSI 8.91rCSI 74.99%PRS 14.11
-
CSI 8.48rCSI 16.01%PRS 17.69
-
CSI 8.39rCSI 15.71%PRS 10.33
-
CSI 8.11rCSI 6.8%PRS 17.02
-
CSI 8.07rCSI 53.55%PRS 14.35
-
CSI 7.99rCSI 23.72%PRS 20.56
-
CSI 7.94rCSI 12.15%PRS 23.09
-
CSI 7.64rCSI 12.2%PRS 15.58
-
CSI 7.61rCSI 23.45%PRS 21.53
-
CSI 7.36rCSI 19.11%PRS 18.71
-
CSI 7.3rCSI 4.85%PRS 17.02
-
CSI 7.08rCSI 31.12%PRS 10.92
-
CSI 6.94rCSI 5.84%PRS 22.86
-
CSI 6.92rCSI 4.81%PRS 16.7
-
CSI 6.57rCSI 93.22%PRS 10.14
-
CSI 6.38rCSI 31.45%PRS 19.3
-
CSI 6.33rCSI 16.26%PRS 19.58
-
CSI 6.3rCSI 15.03%PRS 16.9
-
CSI 6.24rCSI 25.71%PRS 42.96
-
CSI 6.15rCSI 96.91%PRS 8.45
-
CSI 6.09rCSI 37.52%PRS 37.32
-
CSI 5.79rCSI 7.27%PRS 57.5
-
CSI 5.74rCSI 12.87%PRS 8.76
-
CSI 5.7rCSI 4.89%PRS 24.52
-
CSI 5.51rCSI 4.45%PRS 14.09
-
CSI 5.45rCSI 62.41%PRS 14.63
-
CSI 5.33rCSI 20.72%PRS 19.74
-
CSI 5.21rCSI 13.47%PRS 13.28
-
CSI 5.21rCSI 15.37%PRS 17.31
-
CSI 5.13rCSI 3.99%PRS 20.49
-
CSI 5.07rCSI 12.39%PRS 14.12
-
CSI 5.06rCSI 17.11%PRS 23.45
-
CSI 5.01rCSI 30.29%PRS 31.51
-
CSI 4.95rCSI 13.24%PRS 11.94
-
CSI -10.4rCSI -15.2%PRS 15.0%
-
CSI -3.8rCSI -9.7%PRS 14.4%
-
CSI -3.4rCSI -5.4%PRS 33.9%
-
CSI -3.3rCSI -5.3%PRS 12.3%
-
CSI -2.9rCSI -5.2%PRS 36.8%
-
CSI -2.8rCSI -21.1%PRS 47.3%
-
CSI -2.7rCSI -4.6%PRS 28.2%
-
CSI -2.3rCSI -9.5%PRS 28.5%
-
CSI -2.2rCSI -6.3%PRS 31.3%
-
CSI -1.9rCSI -1.9%PRS 22.3%
-
CSI -1.8rCSI -2.5%PRS 14.7%
-
CSI -1.7rCSI -3.7%PRS 16.2%
-
CSI -1.6rCSI -3.6%PRS 14.8%
-
CSI -1.2rCSI -2.7%PRS 21.7%
-
CSI -1.1rCSI -1.0%PRS 16.4%
-
CSI -0.7rCSI -1.0%PRS 15.8%
-
CSI -0.7rCSI -3.4%PRS 25.3%
-
CSI -0.5rCSI -1.3%PRS 40.3%
-
CSI -0.5rCSI -2.5%PRS 25.5%
-
CSI -0.3rCSI -5.2%PRS 51.7%
-
CSI -0.1rCSI -0.5%PRS 33.2%
-
CSI 0.1rCSI 1.2%PRS 64.6%
-
CSI 0.1rCSI 0.1%PRS 65.6%
-
CSI 0.1rCSI 1.5%PRS 53.2%
-
CSI 0.1rCSI 1.2%PRS 44.5%
-
CSI 0.1rCSI 1.0%PRS 51.7%
-
CSI 0.1rCSI 1.0%PRS 25.6%
-
CSI 0.1rCSI 0.6%PRS 34.7%
-
CSI 0.1rCSI 0.1%PRS 29.3%
-
CSI 0.1rCSI 0.7%PRS 21.8%
-
CSI 0.1rCSI 0.8%PRS 44.2%
-
CSI 0.1rCSI 0.8%PRS 21.4%
-
CSI 0.2rCSI 0.8%PRS 18.6%
-
CSI 0.2rCSI 0.3%PRS 22.9%
-
CSI 0.2rCSI 0.8%PRS 46.5%
-
CSI 0.2rCSI 1.0%PRS 11.2%
-
CSI 0.2rCSI 0.3%PRS 21.8%
-
CSI 0.2rCSI 3.2%PRS 34.9%
-
CSI 0.2rCSI 1.5%PRS 42.5%
-
CSI 0.2rCSI 0.9%PRS 30.7%
-
CSI 0.2rCSI 0.3%PRS 12.5%
-
CSI 0.2rCSI 0.3%PRS 18.7%
-
CSI 0.2rCSI 6.2%PRS 60.6%
-
CSI 0.2rCSI 2.6%PRS 19.5%
-
CSI 0.3rCSI 0.4%PRS 19.7%
-
CSI 0.3rCSI 0.4%PRS 14.1%
-
CSI 0.3rCSI 1.7%PRS 40.0%
-
CSI 0.3rCSI 0.7%PRS 28.4%
-
CSI 0.3rCSI 2.1%PRS 36.4%
-
CSI 0.3rCSI 1.7%PRS 24.9%
-
CSI 0.3rCSI 0.3%PRS 15.2%
-
CSI 0.3rCSI 1.5%PRS 38.6%
-
CSI 0.3rCSI 3.7%PRS 35.1%
-
CSI 0.3rCSI 1.1%PRS 20.7%
-
CSI 0.3rCSI 2.1%PRS 44.9%
-
CSI 0.4rCSI 0.8%PRS 19.0%
-
CSI 0.4rCSI 0.5%PRS 22.8%
-
CSI 0.4rCSI 0.4%PRS 10.4%
-
CSI 0.4rCSI 1.1%PRS 11.7%
-
CSI 0.4rCSI 1.6%PRS 26.9%
-
CSI 0.4rCSI 0.4%PRS 12.2%
-
CSI 0.4rCSI 2.3%PRS 20.7%
-
CSI 0.4rCSI 4.9%PRS 51.9%
-
CSI 0.5rCSI 0.7%PRS 20.1%
-
CSI 0.5rCSI 2.6%PRS 47.7%
-
CSI 0.5rCSI 4.1%PRS 6.6%
-
CSI 0.5rCSI 2.1%PRS 48.6%
-
CSI 0.5rCSI 2.0%PRS 19.3%
-
CSI 0.5rCSI 1.2%PRS 21.4%
-
CSI 0.5rCSI 1.3%PRS 17.0%
-
CSI 0.5rCSI 0.7%PRS 16.4%
-
CSI 0.5rCSI 0.4%PRS 17.1%
-
CSI 0.5rCSI 1.4%PRS 23.2%
-
CSI 0.5rCSI 0.9%PRS 14.0%
-
CSI 0.6rCSI 1.5%PRS 27.7%
-
CSI 0.6rCSI 0.7%PRS 15.6%
-
CSI 0.6rCSI 0.8%PRS 11.0%
-
CSI 0.6rCSI 2.2%PRS 14.3%
-
CSI 0.6rCSI 4.3%PRS 38.2%
-
CSI 0.6rCSI 0.7%PRS 13.1%
-
CSI 0.6rCSI 1.1%PRS 18.8%
-
CSI 0.6rCSI 1.1%PRS 16.6%
-
CSI 0.6rCSI 9.4%PRS 35.1%
-
CSI 0.7rCSI 1.6%PRS 13.1%
-
CSI 0.7rCSI 0.8%PRS 21.7%
-
CSI 0.7rCSI 0.9%PRS 33.8%
-
CSI 0.7rCSI 4.1%PRS 22.4%
-
CSI 0.7rCSI 1.5%PRS 13.3%
-
CSI 0.7rCSI 0.9%PRS 20.0%
-
CSI 0.7rCSI 0.9%PRS 15.0%
-
CSI 0.7rCSI 16.6%PRS 46.3%
-
CSI 0.7rCSI 1.6%PRS 29.2%
-
CSI 0.7rCSI 3.1%PRS 14.0%
-
CSI 0.7rCSI 4.5%PRS 32.7%
-
CSI 0.7rCSI 2.0%PRS 20.7%
-
CSI 0.7rCSI 3.1%PRS 13.7%
-
CSI 0.7rCSI 2.0%PRS 24.4%
-
CSI 0.7rCSI 3.1%PRS 25.4%
-
CSI 0.7rCSI 1.1%PRS 16.7%
-
CSI 0.7rCSI 3.0%PRS 19.0%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 3712659903
Symbol: MYCB2_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 9689053
Title: Identification of a large Myc-binding protein that contains RCC1-like repeats.
PubMed ID: 9689053
PubMed ID: 15057823
Title: The DNA sequence and analysis of human chromosome 13.
PubMed ID: 15057823
DOI: 10.1038/nature02379
PubMed ID: 10048485
Title: Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.
PubMed ID: 10048485
PubMed ID: 12168954
Title: Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.
PubMed ID: 12168954
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 11042152
Title: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells.
PubMed ID: 11042152
DOI: 10.1101/gr.140200
PubMed ID: 14559897
Title: Pam and its ortholog highwire interact with and may negatively regulate the TSC1.TSC2 complex.
PubMed ID: 14559897
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 18308511
Title: Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling.
PubMed ID: 18308511
PubMed ID: 18691976
Title: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
PubMed ID: 18691976
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19398581
Title: Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal development.
PubMed ID: 19398581
DOI: 10.1128/mcb.00364-09
PubMed ID: 19369195
Title: Large-scale proteomics analysis of the human kinome.
PubMed ID: 19369195
PubMed ID: 19690332
Title: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
PubMed ID: 19690332
PubMed ID: 20534529
Title: E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb alpha.
PubMed ID: 20534529
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 21406692
Title: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
PubMed ID: 21406692
PubMed ID: 22357847
Title: RAE-1, a novel PHR binding protein, is required for axon termination and synapse formation in Caenorhabditis elegans.
PubMed ID: 22357847
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 26304119
Title: MYCBP2 is a guanosine exchange factor for Ran protein and determines its localization in neurons of dorsal root ganglia.
PubMed ID: 26304119
PubMed ID: 27278822
Title: The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway.
PubMed ID: 27278822
DOI: 10.1038/ncomms11803
PubMed ID: 29293652
Title: USP11 deubiquitinates RAE1 and plays a key role in bipolar spindle formation.
PubMed ID: 29293652
PubMed ID: 29643511
Title: Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity.
PubMed ID: 29643511
Sequence Information:
- Length: 4678
- Mass: 513636
- Checksum: F76B95A12613E74B
- Sequence:
MMMCAATASP AAASSGLGGD GFYPAATFSS SPAPGALFMP VPDGSVAAAG LGLGLPAADS RGHYQLLLSG RALADRYRRI YTAALNDRDQ GGGSAGHPAS RNKKILNKKK LKRKQKSKSK VKTRSKSENL ENTVIIPDIK LHSNPSAFNI YCNVRHCVLE WQKKEISLAA ASKNSVQSGE SDSDEEEESK EPPIKLPKII EVGLCEVFEL IKETRFSHPS LCLRSLQALL NVLQGQQPEG LQSEPPEVLE SLFQLLLEIT VRSTGMNDST GQSLTALSCA CLFSLVASWG ETGRTLQAIS AILTNNGSHA CQTIQVPTIL NSLQRSVQAV LVGKIQIQDW FSNGIKKAAL MHKWPLKEIS VDEDDQCLLQ NDGFFLYLLC KDGLYKIGSG YSGTVRGHIY NSTSRIRNRK EKKSWLGYAQ GYLLYRDVNN HSMTAIRISP ETLEQDGTVM LPDCHTEGQN ILFTDGEYIN QIAASRDDGF VVRIFATSTE PVLQQELQLK LARKCLHACG ISLFDLEKDL HIISTGFDEE SAILGAGREF ALMKTANGKI YYTGKYQSLG IKQGGPSAGK WVELPITKSP KIVHFSVGHD GSHALLVAED GSIFFTGSAS KGEDGESTKS RRQSKPYKPK KIIKMEGKIV VYTACNNGSS SVISKDGELY MFGKDAIYSD SSSLVTDLKG HFVTQVAMGK AHTCVLMKNG EVWTFGVNNK GQCGRDTGAM NQGGKGFGVE NMATAMDEDL EEELDEKDEK SMMCPPGMHK WKLEQCMVCT VCGDCTGYGA SCVSSGRPDR VPGGICGCGS GESGCAVCGC CKACARELDG QEARQRGILD AVKEMIPLDL LLAVPVPGVN IEEHLQLRQE EKRQRVIRRH RLEEGRGPLV FAGPIFMNHR EQALARLRSH PAQLKHKRDK HKDGSGERGE KDASKITTYP PGSVRFDCEL RAVQVSCGFH HSVVLMENGD VYTFGYGQHG QLGHGDVNSR GCPTLVQALP GPSTQVTAGS NHTAVLLMDG QVFTFGSFSK GQLGRPILDV PYWNAKPAPM PNIGSKYGRK ATWIGASGDQ TFLRIDEALI NSHVLATSEI FASKHIIGLV PASISEPPPF KCLLINKVDG SCKTFNDSEQ EDLQGFGVCL DPVYDVIWRF RPNTRELWCY NAVVADARLP SAADMQSRCS ILSPELALPT GSRALTTRSH AALHILGCLD TLAAMQDLKM GVASTEEETQ AVMKVYSKED YSVVNRFESH GGGWGYSAHS VEAIRFSADT DILLGGLGLF GGRGEYTAKI KLFELGPDGG DHETDGDLLA ETDVLAYDCA AREKYAMMFD EPVLLQAGWW YVAWARVSGP SSDCGSHGQA SITTDDGVVF QFKSSKKSNN GTDVNAGQIP QLLYRLPTSD GSASKGKQQT SEPVHILKRS FARTVSVECF ESLLSILHWS WTTLVLGVEE LRGLKGFQFT ATLLDLERLR FVGTCCLRLL RVYTCEIYPV SATGKAVVEE TSKLAECIGK TRTLLRKILS EGVDHCMVKL DNDPQGYLSQ PLSLLEAVLQ ECHNTFTACF HSFYPTPALQ WACLCDLLNC LDQDIQEANF KTSSSRLLAA VMSALCHTSV KLTSIFPIAY DGEVLLRSIV KQVSTENDST LVHRFPLLVA HMEKLSQSEE NISGMTSFRE VLEKMLVIVV LPVRNSLRRE NELFSSHLVS NTCGLLASIV SELTASALGS EVDGLNSLHS VKASANRFTK TSQGRSWNTG NGSPDAICFS VDKPGIVVVG FSVYGGGGIH EYELEVLVDD SEHAGDSTHS HRWTSLELVK GTYTTDDSPS DIAEIRLDKV VPLKENVKYA VRLRNYGSRT ANGDGGMTTV QCPDGVTFTF STCSLSSNGT NQTRGQIPQI LYYRSEFDGD LQSQLLSKAN EEDKNCSRAL SVVSTVVRAS KDLLHRALAV DADDIPELLS SSSLFSMLLP LIIAYIGPVA AAIPKVAVEV FGLVQQLLPS VAILNQKYAP PAFNPNQSTD STTGNQPEQG LSACTTSSHY AVIESEHPYK PACVMHYKVT FPECVRWMTI EFDPQCGTAQ SEDVLRLLIP VRTVQNSGYG PKLTSVHENL NSWIELKKFS GSSGWPTMVL VLPGNEALFS LETASDYVKD DKASFYGFKC FAIGYEFSPG PDEGVIQLEK ELANLGGVCA AALMKKDLAL PIGNELEEDL EILEEAALQV CKTHSGILGK GLALSHSPTI LEALEGNLPL QIQSNEQSFL DDFIACVPGS SGGRLARWLQ PDSYADPQKT SLILNKDDIR CGWPTTITVQ TKDQYGDVVH VPNMKVEVKA VPVSQKKMSL QQDQAKKPQR IPGSPAVTAA SSNTDMTYGG LASPKLDVSY EPMIVKEARY IAITMMKVYE NYSFEELRFA SPTPKRPSEN MLIRVNNDGT YCANWTPGAI GLYTLHVTID GIEIDAGLEV KVKDPPKGMI PPGTQLVKPK SEPQPNKVRK FVAKDSAGLR IRSHPSLQSE QIGIVKVNGT ITFIDEIHND DGVWLRLNDE TIKKYVPNMN GYTEAWCLSF NQHLGKSLLV PVDESKTNTD DFFKDINSCC PQEATMQEQD MPFLRGGPGM YKVVKTGPSG HNIRSCPNLR GIPIGMLVLG NKVKAVGEVT NSEGTWVQLD QNSMVEFCES DEGEAWSLAR DRGGNQYLRH EDEQALLDQN SQTPPPSPFS VQAFNKGASC SAQGFDYGLG NSKGDRGNIS TSSKPASTSG KSELSSKHSR SLKPDGRMSR TTADQKKPRG TESLSASESL ILKSDAAKLR SDSHSRSLSP NHNTLQTLKS DGRMPSSSRA ESPGPGSRLS SPKPKTLPAN RSSPSGASSP RSSSPHDKNL PQKSTAPVKT KLDPPRERSK SDSYTLDPDT LRKKKMPLTE PLRGRSTSPK PKSVPKDSTD SPGSENRAPS PHVVQENLHS EVVEVCTSST LKTNSLTDST CDDSSEFKSV DEGSNKVHFS IGKAPLKDEQ EMRASPKISR KCANRHTRPK KEKSSFLFKG DGSKPLEPAK QAMSPSVAEC ARAVFASFLW HEGIVHDAMA CSSFLKFHPE LSKEHAPIRS SLNSQQPTEE KETKLKNRHS LEISSALNMF NIAPHGPDIS KMGSINKNKV LSMLKEPPLH EKCEDGKTET TFEMSMHNTM KSKSPLPLTL QHLVAFWEDI SLATIKAASQ NMIFPSPGSC AVLKKKECEK ENKKSKKEKK KKEKAEVRPR GNLFGEMAQL AVGGPEKDTI CELCGESHPY PVTYHMRQAH PGCGRYAGGQ GYNSIGHFCG GWAGNCGDGG IGGSTWYLVC DRCREKYLRE KQAAAREKVK QSRRKPMQVK TPRALPTMEA HQVIKANALF LLSLSSAAEP SILCYHPAKP FQSQLPSVKE GISEDLPVKM PCLYLQTLAR HHHENFVGYQ DDNLFQDEMR YLRSTSVPAP YISVTPDASP NVFEEPESNM KSMPPSLETS PITDTDLAKR TVFQRSYSVV ASEYDKQHSI LPARVKAIPR RRVNSGDTEV GSSLLRHPSP ELSRLISAHS SLSKGERNFQ WPVLAFVIQH HDLEGLEIAM KQALRKSACR VFAMEAFNWL LCNVIQTTSL HDILWHFVAS LTPAPVEPEE EEDEENKTSK ENSEQEKDTR VCEHPLSDIV IAGEAAHPLP HTFHRLLQTI SDLMMSLPSG SSLQQMALRC WSLKFKQSDH QFLHQSNVFH HINNILSKSD DGDSEESFSI SIQSGFEAMS QELCIVMCLK DLTSIVDIKT SSRPAMIGSL TDGSTETFWE SGDEDKNKTK NITINCVKGI NARYVSVHVD NSRDLGNKVT SMTFLTGKAV EDLCRIKQVD LDSRHIGWVT SELPGGDNHI IKIELKGPEN TLRVRQVKVL GWKDGESTKI AGQISASVAQ QRNCEAETLR VFRLITSQVF GKLISGDAEP TPEQEEKALL SSPEGEEKVY NATSDADLKE HMVGIIFSRS KLTNLQKQVC AHIVQAIRME ATRVREEWEH AISSKENANS QPNDEDASSD AYCFELLSMV LALSGSNVGR QYLAQQLTLL QDLFSLLHTA SPRVQRQVTS LLRRVLPEVT PSRLASIIGV KSLPPADISD IIHSTEKGDW NKLGILDMFL GCIAKALTVQ LKAKGTTITG TAGTTVGKGV TTVTLPMIFN SSYLRRGESH WWMKGSTPTQ ISEIIIKLIK DMAAGHLSEA WSRVTKNAIA ETIIALTKME EEFRSPVRCI ATTRLWLALA SLCVLDQDHV DRLSSGRWMG KDGQQKQMPM CDNHDDGETA AIILCNVCGN LCTDCDRFLH LHRRTKTHQR QVFKEEEEAI KVDLHEGCGR TKLFWLMALA DSKTMKAMVE FREHTGKPTT SSSEACRFCG SRSGTELSAV GSVCSDADCQ EYAKIACSKT HPCGHPCGGV KNEEHCLPCL HGCDKSATSL KQDADDMCMI CFTEALSAAP AIQLDCSHIF HLQCCRRVLE NRWLGPRITF GFISCPICKN KINHIVLKDL LDPIKELYED VRRKALMRLE YEGLHKSEAI TTPGVRFYND PAGYAMNRYA YYVCYKCRKA YFGGEARCDA EAGRGDDYDP RELICGACSD VSRAQMCPKH GTDFLEYKCR YCCSVAVFFC FGTTHFCNAC HDDFQRMTSI PKEELPHCPA GPKGKQLEGT ECPLHVVHPP TGEEFALGCG VCRNAHTF